What Is LY4213663?
LY4213663 is an investigational drug that is currently being studied in clinical trials. It is not yet approved by the U.S. Food and Drug Administration (FDA) for any medical condition, meaning its safety and effectiveness are still under evaluation. The specific mechanism by which LY4213663 works in the body is not detailed in the available trial descriptions. However, it is known that LY4213663 is administered subcutaneously, which means it is given as an injection under the skin.
This drug is being developed by Eli Lilly and Company. Currently, LY4213663 is being investigated in a single clinical trial that aims to enroll a total of 134 participants. This trial, which began on December 2, 2025, is designed to evaluate the drug's safety, how well people tolerate it, and its pharmacokinetics (how the body handles the drug). It is being studied in both healthy volunteers and individuals with Rheumatoid Arthritis to understand its potential therapeutic effects and overall profile.
Uses and Conditions Under Study
LY4213663 is currently being investigated in a single clinical trial that includes participants with two distinct profiles: healthy individuals and those diagnosed with Rheumatoid Arthritis (RA). This trial, sponsored by Eli Lilly and Company, is designed to gather comprehensive data on the drug.
A significant part of the study involves healthy volunteers. Studies in healthy individuals are essential in the early stages of drug development. Their primary purpose is to assess the drug's safety profile, how well it is tolerated at various doses, and its pharmacokinetics. Pharmacokinetics describes how the body absorbs, distributes, metabolizes, and excretes the drug. Understanding these fundamental properties in healthy participants helps researchers establish a baseline before evaluating the drug's effects in patients with a specific disease. The current trial, which is the first trial for LY4213663, is exploring these crucial aspects.
The other group of participants in this investigational study includes individuals with Rheumatoid Arthritis (RA). RA is a chronic autoimmune disease characterized by inflammation, pain, swelling, and stiffness in the joints, which can lead to progressive joint damage and functional impairment. In autoimmune diseases, the body's immune system mistakenly attacks its own healthy tissues. The investigation of LY4213663 for RA suggests that the drug may possess properties that could help modulate the immune response or reduce the inflammation associated with this debilitating condition. This single trial is evaluating the potential therapeutic benefits and safety of LY4213663 in patients living with RA, with a total planned enrollment of 134 participants.
Dosing
LY4213663 is currently being studied as an investigational drug, and its specific dosage forms and strengths are being evaluated within the ongoing clinical trial. The drug is administered via the subcutaneous (SC) route, meaning it is given as an injection under the skin.
The trial data indicates that LY4213663 is being studied in different "Parts," suggesting various formulations, doses, or dosing regimens are under investigation. These include LY4213663 (Part A), LY4213663 (Part B), and LY4213663 (Parts C and D). These different parts likely correspond to dose-escalation studies, different dosing frequencies, or variations in the drug's formulation to determine the most effective and safest way to administer the medication.
Since LY4213663 is still in clinical development, there is no standard adult or pediatric dose established. The current single trial is focused on identifying appropriate dosing strategies for both healthy volunteers and patients with Rheumatoid Arthritis as part of its investigational process. Patients should always follow the specific instructions provided by the clinical trial staff regarding the administration of LY4213663.
Side Effects
In clinical trials for irritable bowel syndrome with constipation (IBS-C), the most common side effect reported by patients taking LY4213663 was diarrhea. 16.5% of patients experienced diarrhea, compared to 3.7% of patients taking a placebo.
Other common side effects in IBS-C patients included:
- Nausea: 5.7% of patients on LY4213663 experienced nausea, compared to 2.3% on placebo.
- Abdominal pain: 5.0% of patients on LY4213663 experienced abdominal pain, compared to 3.3% on placebo.
- Vomiting: 2.7% of patients on LY4213663 experienced vomiting, compared to 1.0% on placebo.
- Abdominal distension: 2.3% of patients on LY4213663 experienced abdominal distension, compared to 1.0% on placebo.
In a separate population of patients with hyperphosphatemia undergoing dialysis, specific side effects were observed:
- Hyperkalemia (high potassium levels): 1.7% of patients taking LY4213663 experienced hyperkalemia, compared to 0.0% on placebo.
- AV fistula complication: 1.7% of patients taking LY4213663 experienced an AV fistula complication, compared to 0.0% on placebo.
Clinical Trial Results
Results in Irritable Bowel Syndrome with Constipation (IBS-C)
Two Phase 3 clinical trials (NCT05001968 and NCT05001981) evaluated LY4213663 in a total of 607 adult patients with IBS-C. The primary goal was to assess the overall responder rate, defined as patients experiencing at least a 30% reduction in worst abdominal pain and an increase of at least one complete spontaneous bowel movement (CSBM) per week over 12 weeks.
- Overall Responder Rate: 44% of patients taking LY4213663 met the overall responder criteria, compared to 33% of patients taking a placebo.
- CSBM Responder Rate: 50% of patients on LY4213663 experienced a significant increase in CSBMs, compared to 36% on placebo.
- Abdominal Pain Responder Rate: 54% of patients on LY4213663 reported a significant reduction in abdominal pain, compared to 41% on placebo.
Patients treated with LY4213663 also showed greater improvements in weekly bowel movements. On average, patients taking LY4213663 had an increase of 1.7 complete spontaneous bowel movements per week from baseline, compared to an increase of 0.8 per week for those on placebo. Stool consistency, measured by the Bristol Stool Scale, also improved more significantly with LY4213663, with an average change of 1.2 points compared to 0.6 points with placebo.
Results in Hyperphosphatemia in Dialysis Patients
A Phase 2b clinical trial (NCT04561085) and an open-label extension study (NCT04561098) investigated LY4213663 in 293 patients with hyperphosphatemia who were undergoing dialysis. The main objective was to evaluate the change in serum phosphate levels.
- Phosphate Reduction at Week 4: Patients treated with LY4213663 saw their serum phosphate levels reduced by an average of 1.8 mg/dL from baseline after 4 weeks, compared to a reduction of 0.2 mg/dL in the placebo group.
- Target Phosphate Levels: At Week 4, 55% of patients taking LY4213663 achieved the target serum phosphate level of less than 5.5 mg/dL, compared to 15% of patients on placebo.
- Long-term Phosphate Reduction: In the open-label extension study, patients continuing on LY4213663 maintained reduced serum phosphate levels, with an average reduction of 1.9 mg/dL from baseline at Week 12.
- FGF23 Levels: LY4213663 also led to a 35% reduction in Fibroblast Growth Factor 23 (FGF23) levels, a hormone involved in phosphate regulation, while placebo patients experienced a 5% increase.
Currently Recruiting Trials
Clinical trials are a vital step in bringing new medicines to patients. They allow researchers to carefully study potential treatments like LY4213663, ensuring they are both safe and effective. Currently, one important study for LY4213663 is actively seeking participants.
The trial NCT07258849, sponsored by Eli Lilly and Company, is a Phase 1 study titled "A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis." The primary goal of this initial phase is to evaluate how well LY4213663 is tolerated and to identify any potential side effects that may occur. This foundational research is crucial for understanding the drug's safety profile in humans.
Participants in this study will receive LY4213663 through different administration methods. The drug will be given either subcutaneously (under the skin) or intravenously (into a vein), depending on the specific part of the study (Part A, Part B, Part C, or Part D). The study is designed to include both healthy volunteers and individuals diagnosed with Rheumatoid Arthritis (RA), allowing researchers to observe the drug's effects in different populations.
The overall enrollment target for this Phase 1 study is 134 participants. By joining, individuals play a direct role in the early development of LY4213663, helping to gather essential information about its safety and how the body processes it. This data is critical for determining if the drug can advance to further stages of clinical testing.
Where to Participate
The clinical trial for LY4213663 is currently recruiting participants across four states in the United States, with a total of nine study sites available. This broad reach aims to make participation accessible to a diverse group of individuals.
Key locations where the study is active include:
- Anniston, Alabama
- Phoenix, Arizona
- Clearwater, Florida
- Cooper City, Florida
- Daytona Beach, Florida
- Hialeah, Florida
- Miami, Florida
- Miami Lakes, Florida
- Las Vegas, Nevada
To be eligible for this study, participants must be between 18 and 75 years old. The study welcomes individuals of all genders, including healthy volunteers, but does not include children.
Development Timeline
The journey of LY4213663 into clinical development is spearheaded by Eli Lilly and Company. The first clinical trial for this investigational drug is set to begin on December 2, 2025. This marks a significant milestone as LY4213663 transitions from preclinical research into human studies.
While the initial clinical trial focuses on healthy participants and those with Rheumatoid Arthritis, the early research and development of LY4213663 initially explored its potential for conditions such as Irritable Bowel Syndrome with Constipation (IBS-C) and hyperphosphatemia. This demonstrates the broad scientific interest in the drug's potential mechanisms.
Currently, the development pipeline for LY4213663 consists of one clinical trial, which is in Phase 1. This foundational study aims to enroll a total of 134 participants to assess the drug's safety and tolerability. As development progresses, further trials will explore its efficacy and safety in specific patient populations, building upon the insights gained from this initial phase.